ReviewFrontiers in immunology2025
Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic cancer vaccines are increasingly recognized as a highly promising approach for tumor treatment; however, their clinical efficacy critically depends on the rational design of vaccine adjuvants. Natural compounds derived from Traditional Chinese Medicine (TCM) have emerged as attractive candidates for next-generation tumor vaccine adjuvants. In this review, we systematically summarize the chemical constituents of TCM-derived adjuvants reported in current research and categorize their mechanisms of action into four functional modalities: (i) immunostimulatory adjuvants that activate innate immune pathways; (ii) delivery-enhancing systems that improve antigen stability and facilitate targeting to antigen-presenting cells; (iii) integrated platforms that combine both immunostimulatory and delivery-enhancing functions; and (iv) other mechanisms involving non-canonical immunomodulatory activities. We further discuss current challenges in standardization, regulatory approval, and clinical translation, offering a roadmap for harnessing the potential of TCM in the rational design of cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.